Methotrexaat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purine nucleotides and thymidylate, leading to reduced DNA, RNA, and protein production. This effect is most pronounced in rapidly dividing cells, providing both anti‑inflammatory and anticancer activity.

The prescribed dose of Methotrexaat Accord is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and overall treatment plan. No universal dosing schedule is provided; clinicians adjust the regimen to achieve therapeutic goals while minimizing toxicity.

Methotrexate is generally contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after stopping. Breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Methotrexate belongs to the antimetabolite class, targeting folate metabolism, whereas many other chemotherapeutics act on microtubules, DNA cross‑linking, or kinase inhibition. Compared with agents like cyclophosphamide, methotrexate has a distinct toxicity profile, often causing mucosal and hepatic effects, but it can be effective in cancers that are sensitive to folate pathway disruption.

Store Methotrexaat Accord at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions provided on the label to maintain product stability.

Methotrexaat Accord is supplied as a sterile injectable solution and is administered by qualified healthcare professionals via intra‑arterial, intramuscular, or intrathecal injection, depending on the clinical indication. The route, dosage, and frequency are determined by the prescriber based on the patient’s condition and response.

The most serious adverse events include bone‑marrow suppression leading to pancytopenia, severe liver injury, pulmonary fibrosis or interstitial pneumonitis, and life‑threatening infections. Patients should be monitored regularly for blood counts, liver enzymes, and respiratory symptoms, and any concerning signs should prompt immediate medical evaluation.

Methotrexaat Accord should be avoided in patients with severe renal or hepatic impairment, active uncontrolled infections, known hypersensitivity to methotrexate or its excipients, and in women who are pregnant or planning pregnancy without effective contraception. Clinicians must assess each individual’s risk before initiating therapy.